Cyclopharm (ASX:CYC) Loans Receivable: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CYC Cyclopharm Ltd ASX:CYC
43 GF Score
Price A$0.61
GF Value A$0.83
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Loans Receivable?

Cyclopharm ASX:CYC +25.77% 43 Loans Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 43/100 and a GF Value™ of A$0.83 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Cyclopharm's Loans Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Cyclopharm Loans Receivable Historical Data

* Premium members only.

The historical data trend for Cyclopharm's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm Loans Receivable Chart

Cyclopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cyclopharm Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CYC
43GF Score
Cyclopharm Ltd ASX:CYC
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of A$0.00 Mil mean?
Cyclopharm (ASX:CYC) has a Loans Receivable of A$0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Cyclopharm and its competitors.
Is Cyclopharm's Loans Receivable too high?
Cyclopharm's current Loans Receivable is A$0.00 Mil. Overall, Cyclopharm has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Loans Receivable compare to MCK and CAH?
Cyclopharm's Loans Receivable of A$0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Distribution company?
A good Loans Receivable depends on the Medical Distribution industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Cyclopharm and its competitors. Cyclopharm's current Loans Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.83, compared to a current price of A$0.61 — trading 26.5% below its estimated fair value. The current Loans Receivable is A$0.00 Mil. Cyclopharm's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Loans Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.61 is trading 26.5% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Modestly Undervalued.

Key valuation signals for ASX:CYC:

  • Loans Receivable: A$0.00 Mil
  • GF Value™: A$0.83 vs. price of A$0.61 (26.5% below fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
43GF Score

Get the complete analysis for ASX:CYC

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.61
Price
A$0.83
GF Value